Docetaxel polymeric micelle Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Docetaxel polymeric micelle Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether Docetaxel polymeric micelle can convert its Small molecule drug profile and Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Docetaxel polymeric micelle (query alias: Docetaxel polymeric micelle) |
|---|---|
| Modality / target | Small molecule drug; Tubulin; Tubulin modulators, Mitosis inhibitors, Tubulin polymerisation promoters |
| Highest global status | Phase 1 |
| Originator | Samyang Biopharmaceuticals Corp. |
| Active developers | Shandong Hubble Kisen Biological Technology Co Ltd, Shanxi Kangbao Biological Product Co. Ltd., Simcere Pharmaceutical Co., Ltd. |
The MCP disease footprint includes Malignant ascites, Advanced Malignant Solid Neoplasm, HER2-negative breast cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07723248 | Phase 3 | Recruiting | 600 | Radiographic Progression Free Survival assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) |
| NCT07730580 | Phase 2 | Not yet recruiting | 242 | Radiographic Progression-Free Survival |
| NCT07730151 | Phase 2 | Not yet recruiting | 200 | 3-year biochemical progression-free survival (bPFS) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours
Phase 1/2; n=19; evaluation: not stated. Reported fields: Number of Participants With DLTs in Each Module = 0 Participants ; -; Number of Participants With DLTs in Each Module = 0 Participants
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Phase 2/3; n=758; evaluation: not stated. Reported fields: OS(Median) = 11.9 Months (95% Confidence Interval, 10.6 - 14.2); OS(Median) = 11.3 Months (95% Confidence Interval, 9.5 - 13.9); OS(Median): Hazard Ratio (HR) = 0.85(95% CI, 0.68 - 1.06), P-Value = 0.079708
Treatment-related hypomagnesemia and pertuzumab discontinuation in HER2-positive breast cancer: A decade of Appalachian data.
Not Applicable; n=138; evaluation: Negative. Reported fields: Diarrhea = 3.9 % ; Diarrhea = 56.3 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Docetaxel polymeric micelle addresses Malignant ascites, Advanced Malignant Solid Neoplasm, HER2-negative breast cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-09-30 | Boryung completes Sanofi Taxotere takeover, launches global oncology biz | Approved | US$16.0M milestones; US$205.0M stated total |
| 2025-02-18 | 首付近2亿元，贝海生物BEIZRAY——首个成功授权出海美国的改良型新药 | Approved | US$25.0M upfront |
| 2022-02-18 | MGH and Orion will collaborate on a study involving the combination of darolutamide/placebo, androgen-deprivation therapy, and docetaxel for the treatment of metastatic, hormone-sensitive prostate cancer. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
